Cadila Pharmaceuticals clarifies position on Aciloc range, reiterates commitment to patient safety
Ahmedabad : Cadila Pharmaceuticals has reiterated that there is no order prohibiting the manufacture, sale or distribution of its Aciloc 150+ and Aciloc 300+ products. The company continues to comply with all applicable national regulatory requirements and supplies to pharmacies continue uninterrupted.
Cadila Pharmaceuticals reaffirmed that the active pharmaceutical ingredient has always been clearly and prominently declared on the packaging and labels of all Aciloc products in accordance with applicable labelling requirements. The company’s scientific and regulatory teams are engaging with the relevant authorities and examining the matter in detail.
The company clarified that Aciloc 150+ and Aciloc 300+ contain Famotidine, a well-established H2 receptor antagonist with a favourable pharmacokinetic profile, an excellent safety record and a rapid onset of action that provides prompt relief from acid-related symptoms. The respective active ingredients are clearly identified on every pack.
Dr. Arani Chatterjee, President, Cadila Pharmaceuticals Limited, said, “Patient safety remains our highest priority. The active pharmaceutical ingredient is clearly stated on every Aciloc pack in accordance with applicable regulatory requirements. We are working closely with the relevant authorities and extending our full cooperation while reviewing the matter carefully. We remain committed to ensuring continued confidence in the quality, safety and appropriate use of our medicines, while continuing to ensure uninterrupted availability of our products.”
For more than 75 years, Cadila Pharmaceuticals has been a pioneer in the Indian healthcare industry, developing high-quality, affordable medicines while adhering to applicable regulatory standards, robust quality systems and ethical business practices.
Cadila Pharmaceuticals reiterated its commitment to the highest standards of quality, patient safety and regulatory compliance, and said it will continue to work constructively with the relevant authorities.
